Molecular And Genetic Characterization Of Atypical And Anaplastic Meningioma’s Implications For Prognosis And Targeted Therapy

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background

The most frequent primary intracranial tumor is a meningioma’s; however, atypical (WHO grade II) and an plastic (WHO grade III) variants are more aggressive and have increased rates of recurrence and being lethal. The current Histopathological grading is not specific in making predictions. New molecular and genetic profiling has identified key biomarkers potentially used as prognostic refinements, or targets in the personalized medicine strategy.

Objectives

To describe the molecular and genetic repertoire of atypical and an plastic meningioma’s and evaluate their prognostic impact, to inform targeted therapy options.

Study design

A Retrospective Study.

Place and duration of study

Department of Neurosurgery MMC Hospital Mardan from jan 2024 to Jan 2025 KPK PAKISTAN

Methods

Patient-derived tumor samples were classified as having atypical and an plastic meningioma’s and underwent whole exam sequencing, RNA sequencing, and DNA methylation profiling. Key markers (Ki-67, p53, PR) were tested by immunohistochemistry. Molecular alterations were statistically associated with clinical data, such as recurrence and survival. In the bioinformatics analysis, there was one common mutation and signaling pathways. T-tests, Kaplan-Meier survival analysis, and Cox regression modeling statistics were applied to determine statistical significance.

Results

Fifty patients (25 atypical and 25 an plastic). Patients were diagnosed at a mean age of 58.4 years (SD +/- 11.6). The ratio between males and females was 1:1.3. There was a major disparity between the two groups in terms of overall survival (p = 0.038), and plastic meningioma’s were related to a reduced survival rate. The most common mutations were NF2 (47%), deletions of CDKN2A/B (29%) and TERT promoter mutations (18%). Tumor clustering into specific subgroups based on methylation profiling was found to correlate with prognosis.

Conclusion

Atypical and an plastic meningioma’s differ, with molecular and genetic profiles indicating various changes linked to prognosis. The application of these findings into clinical care can positively affect the risk stratification and the development of targeted therapies. It is reasonable to develop this direction further and analyze the validity of these biomarkers and be able to gauge their usefulness in predicting therapeutic response and survival.

Article activity feed